Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399597 | 1.00 | HCRTR2 (0.38) | HCRTR2ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL14113476 | 1.00 | HCRTR2 (0.38) | HCRTR2ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL1399553 | 0.86 | HCRTR2 (0.37) | HCRTR2ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL1399554 | 0.86 | HCRTR2 (0.37) | HCRTR2ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL3303472 | 0.81 | PTGS2 (0.47) | ALDH1A1MAPTDGAT1 | |
| SCHEMBL3303468 | 0.81 | PTGS2 (0.47) | ALDH1A1MAPTDGAT1 | |
| SCHEMBL1399682 | 0.80 | HDAC3 (0.40) | HCRTR2ALDH1A1MAPT | |
| SCHEMBL1399684 | 0.80 | HDAC3 (0.40) | HCRTR2ALDH1A1MAPT | |
| SCHEMBL1399745 | 0.79 | DGAT1 (0.51) | ALDH1A1LMNAMAPTCYP2C9DGAT1 | |
| SCHEMBL1399748 | 0.79 | DGAT1 (0.51) | ALDH1A1LMNAMAPTCYP2C9DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2120911-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | Prosidion Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| WO-2008099221-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | HCRTR2 2310/4885ALDH1A1 112/4885LMNA 3400/4885 |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | HCRTR2 841/4885ALDH1A1 872/4885LMNA 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.